Structure Therapeutics (GPCR) Share-based Compensation (2022 - 2026)

Structure Therapeutics' Share-based Compensation history runs 5 years deep, the most recent figure standing at $11.6 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 96.67% year-over-year to $11.6 million in Q1 2026; TTM through Mar 2026 was $34.7 million, a 612.19% increase from a year earlier, with the FY2025 full-year figure at $75.5 million, up 49.21% from the prior year.
• Share-based Compensation grew to $11.6 million in Q1 2026 per GPCR's latest filing, from $8.1 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $11.6 million in Q1 2026 and bottomed at -$11.3 million in Q4 2024.
• The 5-year median for Share-based Compensation is $2.5 million (2023), against an average of $3.1 million.
• Across the five-year window, Share-based Compensation jumped 308.55% in 2023 and tumbled 636.84% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $623000.0 in 2022, then soared by 236.76% to $2.1 million in 2023, then tumbled by 636.84% to -$11.3 million in 2024, then jumped by 171.64% to $8.1 million in 2025, then surged by 44.24% to $11.6 million in 2026.
• Per Business Quant, the three latest GPCR Share-based Compensation figures stand at $11.6 million (Q1 2026), $8.1 million (Q4 2025), and $7.5 million (Q3 2025).